Posaconazole Superior to Itraconazole for Fungal Prophylaxis Post–Heart Transplant: Study

A new study published in the journal of Open Forum Infectious Diseases found posaconazole to be more effective than itraconazole in reducing fungal infection rates after heart transplantation. Since patients require immunosuppressive therapy to prevent graft rejection which increases the infection risk. Posaconazole offers better protection against these invasive infections in transplant recipients.

Heart transplant patients are susceptible to fungal infections like aspergillosis, due to the immunosuppressive therapies required to prevent organ rejection. For years, itraconazole and posaconazole have both been widely used as oral prophylactic agents, but direct comparisons between the two have remained limited. This study from January 2015 to May 2022 was conducted to address that gap.

This study evaluated 232 heart transplant recipients, with 134 patients receiving itraconazole and 98 receiving posaconazole as part of a standard 3-month antifungal prophylaxis regimen. While the itraconazole group was more likely to have undergone induction immunosuppression and combined heart-kidney transplantation, most other baseline characteristics between the 2 groups were comparable.

The results found patients who were treated with itraconazole to experienced a significantly higher incidence of fungal infections, with 7.4% developing infections when compared to none in the posaconazole group. This difference was statistically significant and highlighted a potentially meaningful clinical benefit for posaconazole.

In addition to infection rates, the need to switch antifungal therapy was also notably higher among itraconazole recipients. About 20.9% of patients in the itraconazole group required a change to an alternative antifungal agent, when compared to just 10.2% in the posaconazole group. This suggests that posaconazole may not only be more effective but also more reliable as a first-line prophylactic option.

However, safety outcomes were similar between the two treatments. The incidence of hepatic dysfunction did not differ significantly between groups. This points towards the improved efficacy of posaconazole which does not come at the cost of increased toxicity.

Overall, the findings of this study support the growing preference for posaconazole in antifungal prophylaxis following heart transplantation. By reducing both infection rates and the need for therapy adjustments, posaconazole may help in streamlining the post-transplant care and improve patient outcomes.

Reference:

Tayyar, R., Drucker, D., Lee, R., Le, T., Teuteberg, J., Khush, K., Luikart, H., Intrieri, T., Moayedi, Y., Alegria, W., Dieringer, T., Henricksen, E., & Subramanian, A. (2026). Comparing efficacy and safety of itraconazole solution versus posaconazole for antifungal prophylaxis after heart transplant. Open Forum Infectious Diseases, ofag104. https://doi.org/10.1093/ofid/ofag104